France vs Serbia: Cause of death, by non-communicable diseases, ages 5-14, male
France
63.0%
in 2021
Serbia
62.7%
in 2021
France rank
22nd
Serbia rank
23rd
Cause of death, by non-communicable diseases, ages 5-14, male over time
- France
- Serbia
How they compare
France currently reports 63.0% against 62.7% in Serbia, a difference of 0.3%.
The two have swapped places 3 times across 6 shared years of data; in 2000 it was Serbia ahead.
France ranks 22nd and Serbia ranks 23rd of 185 countries.
Across the 3 decades both report, France averaged higher in 1 and Serbia in 2.
Head to head by decade
| Decade | France | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 47.6% | 48.1% | 0.5% | Serbia |
| 2010s | 65.7% | 56.4% | 9.4% | France |
| 2020s | 61.2% | 65.6% | 4.4% | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 5-14, male, France or Serbia?
- France, at 63.0% against 62.7% in Serbia as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 5-14, male between France and Serbia?
- 0.3%, with France ahead.
- How many years of comparable data are there for France and Serbia?
- 6 years are reported by both, from 2000 to 2021.
- How do France and Serbia rank globally for cause of death, by non-communicable diseases, ages 5-14, male?
- France ranks 22nd and Serbia ranks 23rd of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 5-14, male (% of total male deaths ages 5-14). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of male deaths ages 5-14 due to non-communicable diseases divided by number of all male deaths ages 5-14, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.